Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on November 7, 2013. The filing serves to announce the Company's financial results for the third quarter of 2013. The registrant is incorporated in Delaware and maintains its principal executive offices in Bothell, Washington.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the issuance of a press release regarding Q3 2013 results.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the specific Q3 2013 financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated November 7, 2013).
- Confirm the Company's current cash runway and burn rate, as these are critical for a biopharmaceutical entity but are not listed in this summary text.
- Review the full press release for any updates on clinical trial progress or regulatory milestones that may accompany the financial results.